Botanix Pharmaceuticals
Judith Plon is an accomplished regulatory affairs professional with extensive experience in the pharmaceutical industry. Currently serving as Principal Consultant at NDA Group AB and Vice President of Regulatory Affairs at Botanix Pharmaceuticals since 2019, Plon has held key roles in regulatory strategy and submissions for new drug and biological products. From 2005 to 2018, Plon was Associate Vice President of Global Regulatory Affairs at Sanofi, leading regulatory activities for Rx to OTC switches. Prior experience includes serving as President and Senior Director at Regulatory Pharma Consultants and various positions at Aventis Pharmaceuticals. Judith Plon holds an MBA in Marketing and a Bachelor of Science in Human Nutrition and Foods, Biology from Rutgers University.
This person is not in any teams
This person is not in any offices
Botanix Pharmaceuticals
Botanix is an ASX-listed dermatology company based in Philadelphia(USA) that is committed to the development and commercialisation of novel treatments for common skin diseases and infections. The Company’s lead product is a novel treatment for primary axillary hyperhidrosis, a medical condition where excessive sweating occurs beyond what is needed to maintain body temperature, which impacts the lives of more than 15 million people in the US alone. This product is backed by successful Phase 3 clinical studies, is already approved in Japan, and is in the final stages of US regulatory clearance. The broader clinical pipeline targets unmet needs in dermatology (including acne, rosacea and dermatitis) as well as infections, and are underpinned by well-controlled, randomised clinical trials. Botanix has attracted a world-class team and significant capital to support the development and commercialisation of its products.